Company Overview and News
KPJ Healthcare Bhd ’s (code: 5878) rebound has taken the counter into bull territory as it crossed the 100-day simple moving average (SMA) in yesterday’s session.
Well equipped: A KPJ operating facility. KPJ digitises its clinical process through KCIS, which holds patient records and treatment orders, among others. Currently, the group is undergoing upgrading works for KCIS and HITS to second generation cloud-computing, which is expected to be completed by year-end.
Yasmin: The top challenges in digital readiness in key industries are the lack of structured approach, unavailable or no prioritised budget and a lack of digitally skilled workforce.
KUALA LUMPUR: KPJ Healthcare , IGB Real Estate Investment Trust (IGB Reit), Caring Pharmacy Group Bhd, Crest Builder Holdings Bhd , Samchem Holdings Bhd and Green Packet Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.
Expansion: A KPJ medical facility. KPJ Healthcare Bhd, the largest private healthcare services provider in Malaysia, will be increasing its capacity in 2018, amid expansion by its competitors. The group’s five new hospitals are likely to commence operations this year. In addition, the expansion of its four existing hospitals is expected to be completed within the first half of the year. -
Online health-care platform monitors patients’ experiences and assists medical tourism in 10 Malaysian cities, Singapore and Hong Kong
Ahmad Zahid is scheduled to witness the symbolic exchange of Memorandum of Agreement (MoA) between QSR Brands Holding (M) Berhad and Telekom Malaysia Berhad, which is the fifth initiative of the Johor state government. — Bernama picJOHOR BAHRU, Oct 13 ― Deputy Prime Minister Datuk Seri Dr Ahmad Zahid Hamidi is scheduled to launch five initiatives of the Johor state government set to bring benefits and secure prosperity for people of the state.
According to a new report published by Allied Market Research, titled, "Medical Tourism Market by Treatment Type: Global Opportunity Analysis and Industry Forecast, 2017-2023 ," the global medical tourism market was valued at $61,172 million in 2016, and is projected to reach $165,345 million by 2023, growing at a CAGR of 15.0% from 2017 to 2023. North America is anticipated to be the highest revenue contributor throughout the forecast period.
MarketWatch: US stocks climbed modestly on Wednesday to record closing highs after the Federal Reserve kept interest rates unchanged and strong earnings reports from Boeing and AT&T. The DJIA rose 97.58 points, or 0.45%, to 21,711.01, the S&P 500 gained 0.7 points, or 0.03%, to 2,477.83 and the Nasdaq added 10.57 points, or 0.16%, to 6,422.75. - Reuters
NEW YORK, July 11, 2017 /PRNewswire/ -- Malaysia Medical Tourism Market: Overview In terms of revenue, the Malaysia medical tourism market is expected to register a CAGR of 30.5% during the forecast period, 2016–2024. The primary objective of the report is to offer insights on the market dynamics that can influence growth of the Malaysia medical tourism market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the Malaysia medical tourism market are presented in the report.
Profitable: Sunway’s healthcare division, namely Sunway Medical, reported a pre-tax profit of RM37.65mil in financial year 2016.
Johor is already famous for its Legoland and Hello Kitty theme parks in Nusajaya. — Reuters picKUALA LUMPUR, June 14 — Like elsewhere in Malaysia, Johor’s economy is seeing a shift from manufacturing to services in recent years, with tourism and its related industries contributing greatly to the state coffers.
WHEN the Mid and Small Cap (MidS) Research Scheme was launched on Thursday, the joint media release from the Securities Commission (SC) and Bursa Malaysia didn’t mention a similar initiative introduced over 12 years ago. In fact, the stock exchange and the SC have a lot to do with the older research scheme too.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...